The final Overall survival analysis data from the phase III PAOLA – 1 study presented by Ledermann showed that the addition of #Olaparib to maintenance bevacizumab (bev) in patients with advanced ovarian cancer who responded to first line platinum based therapy + bev led to a significant overall survival benefit particularly in HRD-positive patients (HR 0.62, OS at 5 y, 65.5 vs 48.4%) regardless of BRCA mutation status.
.png)